No Joy In Bayer/Onyx’s Phase III With Nexavar For Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Second sorafenib failure comes three months after Synta/GlaxoSmithKline’s elesclomol blow-up in the tough-to-crack cancer.